Brief introduction of Nanjing Chang 'ao Pharmaceutical Co., Ltd.

Nanjing Chang 'ao covers an area of 40,000 square meters, with a building area of 6,543,8+0.6 million square meters. The registered capital is USD 65,438+USD 065,438+USD 500,000, and the total investment is USD 25 million. On June 5438+ 10, 2005, Nanjing Changan Aolian and other group companies successfully listed on the main board of Singapore Stock Exchange and became listed companies. In order to meet the needs of the long-term development of the market and enterprises, Nanjing Changao emphasized the transformation of technical projects, developed high-tech products and expanded production scale in a planned and step-by-step manner, and * * * carried out four phases of project construction. At present, the production lines with national GMP certification are: ordinary capsules (annual output of 65.438+68 million tablets), penicillin capsules (annual output of 269 million tablets), cephalosporin capsules (annual output of 67 million tablets), ordinary tablets (annual output of 65.438+85 million tablets), penicillin tablets (annual output of 252 million tablets) and cephalosporin tablets (annual output/kloc). Freeze-dried powder injection (annual output of cephalosporin powder injection (annual output of10.4 million tablets), ointment, gel (annual output of 8 million tablets) and raw material medicine workshop (including hormones) produce sibutrazol hydrochloride.

At present, there are more than 40 products of different specifications sold under the Chang 'ao brand, including seven national second-class new drugs. Sibutramine Hydrochloride Capsule, a national second-class medicine, was included in the innovation fund project of the Ministry of Science and Technology and won the second prize of Nanjing Science and Technology Progress Award. Pantoprazole sodium for injection won the title of excellent new product in Nanjing; 200 1, sibutramine hydrochloride capsules and pantoprazole sodium for injection were recognized as high-tech products in Nanjing. In 2002, sibutramine hydrochloride capsules, clarithromycin dispersible tablets and pantoprazole sodium for injection were recognized as high-tech products in Jiangsu Province.

Scientific and technological progress is the foundation of the company's development. From 200 1, the company established "Nanjing Chang 'ao Pharmaceutical Technology Co., Ltd." with 95% equity. The company implements an internal operation mechanism that meets international standards. Cooperate with drug research and development institutions in the United States, Canada, Switzerland and other countries, and cooperate with Shanghai Institute of Pharmacology, China Academy of Sciences, China Pharmaceutical University and a number of outstanding private scientific research institutes. It has laid a solid foundation for the company's development in the next twenty years. Two new drugs, ZLR-8 (anti-inflammatory and analgesic) and PNA (anti-hepatitis), which have patent rights for compounds, have made breakthroughs. A new drug YC- 12 (antibiotic) was developed, and its antibacterial activity was 4-8 times that of vancomycin, which was listed in the "National 863 Project". The research of three first-class new drugs shows bright prospects.

With scientific and efficient management, strong marketing network and solid drug research institutions, the company has established a competitive advantage in the market. Companies adhere to the "people-oriented", creating a unique management model, scientific and standardized management and operation. Company operators regard honesty as their lifeblood and have a good reputation in Nanjing's medical and financial circles. Provincial and municipal leaders have visited many times and given full affirmation and high praise, and have been rated as advanced enterprises in Nanjing for many times. In 200 1 year, the company was recognized as a high-tech enterprise in Nanjing, a high-tech enterprise in Jiangsu Province in 2002, a private high-tech enterprise in Jiangsu Province in 2003, an advanced technology enterprise with foreign investment in Nanjing in 2004, and a technology-intensive and knowledge-intensive enterprise with foreign investment in Jiangsu Province in 2005.